Exicure (XCUR) Competitors $4.07 +0.19 (+4.90%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. ANRO, SRZN, EXOZ, CNTB, IPA, STTK, KALA, ANIX, VIRI, and ORMPShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Alto Neuroscience (ANRO), Surrozen (SRZN), eXoZymes (EXOZ), Connect Biopharma (CNTB), ImmunoPrecise Antibodies (IPA), Shattuck Labs (STTK), KALA BIO (KALA), Anixa Biosciences (ANIX), Virios Therapeutics (VIRI), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Alto Neuroscience Surrozen eXoZymes Connect Biopharma ImmunoPrecise Antibodies Shattuck Labs KALA BIO Anixa Biosciences Virios Therapeutics Oramed Pharmaceuticals Alto Neuroscience (NYSE:ANRO) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends. Which has better earnings and valuation, ANRO or XCUR? Exicure has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.39-1.54Exicure$500K51.44-$9.70M-$3.88-1.05 Which has more risk & volatility, ANRO or XCUR? Alto Neuroscience has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500. Comparatively, Exicure has a beta of 3.85, meaning that its stock price is 285% more volatile than the S&P 500. Do analysts prefer ANRO or XCUR? Alto Neuroscience presently has a consensus price target of $8.50, suggesting a potential upside of 131.61%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, research analysts clearly believe Alto Neuroscience is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ANRO or XCUR more profitable? Alto Neuroscience's return on equity of -44.34% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -44.34% -36.73% Exicure N/A -192.16%-84.30% Does the media favor ANRO or XCUR? In the previous week, Alto Neuroscience had 33 more articles in the media than Exicure. MarketBeat recorded 34 mentions for Alto Neuroscience and 1 mentions for Exicure. Exicure's average media sentiment score of 1.89 beat Alto Neuroscience's score of 0.21 indicating that Exicure is being referred to more favorably in the news media. Company Overall Sentiment Alto Neuroscience Neutral Exicure Very Positive Do insiders and institutionals have more ownership in ANRO or XCUR? 42.8% of Exicure shares are held by institutional investors. 8.4% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAlto Neuroscience and Exicure tied by winning 7 of the 14 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.28M$3.12B$5.74B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-1.0321.3675.3126.23Price / Sales51.44249.18459.1990.15Price / CashN/A44.4425.8129.91Price / Book3.639.5313.006.26Net Income-$9.70M-$53.20M$3.29B$270.67M7 Day Performance-5.35%0.26%0.95%2.93%1 Month Performance-38.80%4.11%4.81%6.12%1 Year Performance154.38%9.03%71.37%26.03% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.454 of 5 stars$4.07+4.9%N/A+142.5%$25.28M$500K-1.0350Positive NewsANROAlto Neuroscience2.7537 of 5 stars$3.77-3.0%$8.50+125.2%-71.5%$102.20MN/A-1.58N/ASRZNSurrozen2.9711 of 5 stars$11.71+3.0%$38.50+228.9%+34.8%$100.31M$10.65M-0.8180Positive NewsEXOZeXoZymes1.2226 of 5 stars$11.76-2.0%N/AN/A$98.67M$70K0.0029Gap DownCNTBConnect Biopharma3.7319 of 5 stars$1.74-3.3%$7.00+302.3%+26.8%$96.95M$26.03M0.00110News CoverageShort Interest ↓Analyst RevisionGap UpIPAImmunoPrecise Antibodies2.7863 of 5 stars$2.10+8.5%$4.00+90.9%+212.7%$96.68M$17.59M-3.0880Gap UpSTTKShattuck Labs3.9186 of 5 stars$2.00+6.4%$4.00+100.0%-49.6%$95.80M$5.72M-1.65100Analyst UpgradeShort Interest ↓KALAKALA BIO3.8598 of 5 stars$13.62-5.9%$17.25+26.7%+215.1%$95.47M$3.89M-2.0030Gap UpANIXAnixa Biosciences3.1211 of 5 stars$2.97-0.5%$9.00+203.5%-12.5%$95.47M$210K-7.805Earnings ReportAnalyst RevisionGap UpVIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,409.0%$94.36MN/A-18.155ORMPOramed Pharmaceuticals0.6206 of 5 stars$2.29-0.7%N/A-3.2%$93.69M$1.34M-6.5310 Related Companies and Tools Related Companies Alto Neuroscience Alternatives Surrozen Alternatives eXoZymes Alternatives Connect Biopharma Alternatives ImmunoPrecise Antibodies Alternatives Shattuck Labs Alternatives KALA BIO Alternatives Anixa Biosciences Alternatives Virios Therapeutics Alternatives Oramed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XCUR Stock Alerts